Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma

Published:2022-09-05 Issue:11 Volume:6 Page:3223-3233
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Reincke Marlene¹,Schultheiss Michael¹,Doppler Michael²,Verloh Niklas²,Uller Wibke²,Sturm Lukas¹³^ORCID,Thimme Robert¹,Goetz Christian⁴,Bettinger Dominik¹^ORCID

Affiliation:

1. Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany

2. Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany

3. Berta‐Ottenstein‐Programme, Faculty of Medicine University of Freiburg Freiburg Germany

4. Department of Nuclear Medicine, Medical Center University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.2072

Reference26 articles.

1. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival

2. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes

3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial